| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Erythromycin estolate |
Is a |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Erythromycin ethylsuccinate (substance) |
Is a |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Erythromycin stearate |
Is a |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Erythromycin ophthalmic agent |
Is a |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Erythromycin lactobionate |
Is a |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Erythromycin gluceptate |
Is a |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Erythromycin phosphate |
Is a |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Erythromycin measurement |
Component |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| Erythromycin poisoning |
Causative agent (attribute) |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| Accidental erythromycin poisoning |
Causative agent (attribute) |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Intentional erythromycin poisoning |
Causative agent (attribute) |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| intoxication par l'érythromycine d'intention indéterminée |
Causative agent (attribute) |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| Erythromycin adverse reaction |
Causative agent (attribute) |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Erythromycin overdose |
Causative agent (attribute) |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| Accidental erythromycin overdose (disorder) |
Causative agent (attribute) |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| Intentional erythromycin overdose |
Causative agent (attribute) |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| surdose d'érythromycine d'intention indéterminée |
Causative agent (attribute) |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| Product containing erythromycin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| Erythromycin 250 mg gastro-resistant oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Erythromycin 125mg/5mL s/f suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Erythromycin 250mg/5mL s/f suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Erythromycin 500mg/5mL s/f suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Product containing precisely erythromycin (as erythromycin lactobionate) 1 gram/1 vial powder for conventional release solution for injection (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Product containing precisely erythromycin (as erythromycin ethylsuccinate) 25 milligram/1 milliliter conventional release oral suspension (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Product containing precisely erythromycin (as erythromycin ethylsuccinate) 50 milligram/1 milliliter conventional release oral suspension (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Product containing precisely erythromycin (as erythromycin ethylsuccinate) 100 milligram/1 milliliter conventional release oral suspension (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Erythromycin [2] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Erythromycin [skin] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Product containing precisely erythromycin 20 milligram/1 milliliter conventional release cutaneous solution (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Erythromycin 40 mg/mL and zinc acetate 12 mg/mL cutaneous solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Erythromycin 3% in benzoyl peroxide topical gel |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Product containing precisely erythromycin 40 milligram/1 gram conventional release cutaneous gel (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Product containing precisely erythromycin 40 milligram/1 gram and tretinoin 250 microgram/1 gram conventional release cutaneous solution (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Erythromycin-containing product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| Erythromycin-containing product in parenteral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| Product containing erythromycin in topical dosage form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Product containing precisely erythromycin 333 milligram/1 each gastro-resistant oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Erythromycin 333mg polymer coated particle tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Erythromycin 500mg polymer coated particle tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Erythromycin 250mg m/r capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Erythromycin 2% gel |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Product containing precisely erythromycin 20 microgram/1 milligram conventional release cutaneous ointment (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Product containing precisely erythromycin 15 milligram/1 milliliter conventional release cutaneous solution (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Erythromycin 5 mg/g cutaneous ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Erythromycin 20mg/mL |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Erythromycin 500 mg gastro-resistant oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Benzoyl peroxide + erythromycin 50mg/30mg gel |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Erythromycin ethylsuccinate + sulfisoxazole acetyl 200mg/600mg oral suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Allergy to erythromycin |
Causative agent (attribute) |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Product containing erythromycin and isotretinoin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| Product containing erythromycin and tretinoin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| Product containing erythromycin and zinc acetate (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| Product containing benzoyl peroxide and erythromycin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely erythromycin 20 milligram/1 gram conventional release cutaneous gel (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Erythromycin 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Erythromycin 250mg e/c granules in capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Product containing precisely erythromycin 20 milligram/1 milliliter conventional release cutaneous lotion (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Accidental erythromycin poisoning |
Causative agent (attribute) |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| Intentional erythromycin poisoning |
Causative agent (attribute) |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| Erythromycin adverse reaction (disorder) |
Causative agent (attribute) |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| Erythromycin sensitivity |
Causative agent (attribute) |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| Product containing erythromycin in ophthalmic dosage form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Allergy to erythromycin |
Causative agent (attribute) |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| Erythromycin 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| Erythromycin 500 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely erythromycin (as erythromycin stearate) 250 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| Erythromycin (as erythromycin stearate) 500 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| Erythromycin dihydrate (substance) |
Is a |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Erythromycin propionate (substance) |
Is a |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Erythromycin lactobionate |
This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged. |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Erythromycin dihydrate (substance) |
This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged. |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Erythromycin phosphate |
This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged. |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Erythromycin propionate (substance) |
This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged. |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Erythromycin stearate |
This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged. |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Erythromycin gluceptate |
This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged. |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Erythromycin ethylsuccinate (substance) |
This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged. |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Erythromycin estolate |
This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged. |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Erythromycin 250mg gastro-resistant oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
|
| Erythromycin 250 mg gastro-resistant oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| Erythromycin 250 mg gastro-resistant oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| Erythromycin 500 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely erythromycin (as erythromycin lactobionate) 1 gram/1 vial powder for conventional release solution for injection (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely erythromycin (as erythromycin ethylsuccinate) 100 milligram/1 milliliter conventional release oral suspension (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely erythromycin (as erythromycin ethylsuccinate) 25 milligram/1 milliliter conventional release oral suspension (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely erythromycin (as erythromycin ethylsuccinate) 50 milligram/1 milliliter conventional release oral suspension (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely erythromycin 20 milligram/1 milliliter conventional release cutaneous solution (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely erythromycin 20 milligram/1 milliliter conventional release cutaneous solution (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely erythromycin 20 milligram/1 gram conventional release cutaneous gel (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely erythromycin 20 milligram/1 gram conventional release cutaneous gel (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely erythromycin 40 milligram/1 gram conventional release cutaneous gel (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely erythromycin 40 milligram/1 gram conventional release cutaneous gel (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely erythromycin 40 milligram/1 gram and tretinoin 250 microgram/1 gram conventional release cutaneous solution (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
2 |
| Product containing precisely erythromycin 40 milligram/1 gram and tretinoin 250 microgram/1 gram conventional release cutaneous solution (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
2 |
| Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
2 |
| Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
2 |
| Erythromycin 40 mg/mL and zinc acetate 12 mg/mL cutaneous solution |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
2 |
| Erythromycin 40 mg/mL and zinc acetate 12 mg/mL cutaneous solution |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Erythromycin (substance) |
Inferred relationship |
Some |
2 |
| Product containing erythromycin and sulfafurazole (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| Erythromycin-containing product in ocular dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
| Product containing erythromycin in cutaneous dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Erythromycin (substance) |
Inferred relationship |
Some |
1 |
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.22-SNAPSHOT
|
FHIR Version n/a
User: [n/a]